Key result
Lifestyle changes plus insulin sensitizers like metformin and rosiglitazone improve clinical symptoms and correct metabolic dysfunction in non-obese women with PCOS and insulin resistance.
Why the study?
Does lifestyle plus insulin sensitizers improve clinical symptoms and metabolic dysfunction in non-obese women with PCOS and insulin resistance?
Does lifestyle plus insulin sensitizers improve clinical symptoms and metabolic dysfunction in non-obese women with PCOS and insulin resistance?
Lifestyle modifications combined with insulin sensitizers like metformin may improve clinical and metabolic outcomes in non-obese women with PCOS and insulin resistance.
Answers are grounded in this paper and cite their sources.
Supports consideration of lifestyle plus metformin in non-obese PCOS with IR; leaves open need for RCTs to confirm benefit.
For non-obese PCOS insulin resistance patients, screening of anthropometric and metabolic parameters is necessary. For PCOS with insulin resistance, lifestyle plus insulin sensitizers such as metformin could improve their clinical symptoms, correct the biochemical and metabolic dysfunction.
No takes yet. Share an insight, caveat, or question.
Tan et al. (2021) studied this question. Lifestyle changes plus insulin sensitizers like metformin and rosiglitazone improve clinical symptoms and correct metabolic dysfunction in non-obese women with PCOS and insulin resistance.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: